Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2019-07-09 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated July 9, 2019, announcing a development milestone in a collaboration between MedinCell and Teva regarding an antipsychotic treatment (mdc-ANG). It details the entry into preclinical development and mentions other products in the pipeline. This type of announcement, focusing on R&D progress, partnerships, or specific operational updates that are not standard periodic financial reports (like 10-K or IR) or mandatory regulatory filings (like DIRS or DIV), typically falls under general corporate news or investor relations updates. Since it is not a formal financial report, earnings release, or a specific transaction notice, it is best classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard corporate news releases, or potentially Investor Presentation (IP) if it were structured as a presentation, but given the format, RNS is the most appropriate fallback for a press release detailing operational progress.
2019-07-09 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Share Issue/Capital Change Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité de la société MEDINCELL" (Half-yearly balance sheet of the liquidity contract of MEDINCELL company) and reports on the status of a liquidity contract (market making/share buyback agreement) as of June 30, 2019, comparing it to the previous balance (December 31, 2018). This type of report details the company's activity regarding its own shares, specifically related to maintaining market liquidity, which falls under the category of transactions in own shares (share repurchase/issuance). The closest matching category is 'Transaction in Own Shares' (POS). It is not a full financial report (IR/10-K) or a general regulatory filing (RNS), but a specific report on share transactions.
2019-07-05 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Monthly information relating to the number of shares comprising the share capital and the total number of voting rights). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the number of shares and voting rights as of May 31, 2019. This content directly relates to reporting changes in share capital and voting rights, which aligns with the definition of Major Shareholding Notification (MRQ) or potentially a specific regulatory filing. However, the core content is a periodic disclosure of the total number of shares and voting rights, which is a standard component of disclosures related to significant share ownership changes or capital structure reporting. Given the options, this specific monthly disclosure about the total number of shares and voting rights is most closely related to tracking ownership thresholds, fitting best under Major Shareholding Notification (MRQ). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS) as it is highly specific to share structure.
2019-06-12 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 95% confidence The document is a press release titled 'MedinCell publie ses résultats financiers annuels 2018/2019'. It provides a summary of financial highlights (cash position, cash burn) and operational updates (clinical trial progress, portfolio development). It explicitly states that it covers elements the company deems essential for evaluating its activity and notes that the full annual financial reports will be issued later. As this is an initial announcement of financial results containing key highlights rather than the full audited annual report, it is classified as an Earnings Release. FY 2019
2019-06-04 French
Inside Information / News release on accounts, results
Earnings Release Classification · 95% confidence The document is titled "MedinCell announces 2018/19 fiscal year results" and provides a summary of financial position ("Strong cash position") and significant clinical/product pipeline progression for the fiscal year ended. It explicitly mentions that the annual and consolidated financial statements have been approved, but the auditors' reports will be issued after procedures for the *annual financial report* are complete. This structure—a high-level summary of annual results, financial highlights, and pipeline updates released around the time of the annual report publication—is characteristic of an Earnings Release (ER) or a preliminary announcement preceding the full 10-K filing. Since it focuses on the *results* and key operational achievements for the period, it fits the definition of an Earnings Release (ER) better than a comprehensive 10-K, which would contain the full audited statements and extensive MD&A. It is not a mere announcement of a report (RPA) because it contains substantial content about the results themselves. FY 2019
2019-06-04 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 95% confidence The document is a short press release (2559 characters) dated May 21, 2019. It announces two key events: 1) The date and details for the shareholder conference call to present the 2018-2019 annual results (June 4, 2019). 2) A change in the date for the Annual General Meeting (AGM) to September 5, 2019. Crucially, it states that the *annual financial report* will be available on the website and AMF site, but the document itself is not the report. Since it announces the publication of results and the AGM date, it fits best as a Report Publication Announcement (RPA) or potentially a Regulatory Filing (RNS). Given that it explicitly mentions the upcoming publication of the annual report and the scheduling of the conference call related to those results, RPA is the most precise fit, as it signals the impending release of the main financial documents.
2019-05-21 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.